Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02414854
Registration number
NCT02414854
Ethics application status
Date submitted
8/04/2015
Date registered
13/04/2015
Date last updated
23/10/2018
Titles & IDs
Public title
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
Query!
Scientific title
A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma
Query!
Secondary ID [1]
0
0
2014-004940-36
Query!
Secondary ID [2]
0
0
EFC13579
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Asthma
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Asthma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Dupilumab
Treatment: Drugs - Placebo
Treatment: Drugs - Inhaled corticosteroid (ICS) therapy
Treatment: Drugs - Albuterol/Salbutamol
Treatment: Drugs - Levalbuterol/Levosalbutamol
Placebo Comparator: Placebo (for Dupilumab 200 mg) q2w - 2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection every 2 weeks (q2w) from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
Experimental: Dupilumab 200 mg q2w - 2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
Placebo Comparator: Placebo (for Dupilumab 300 mg) q2w - 2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
Experimental: Dupilumab 300 mg q2w - 2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines . Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
Treatment: Drugs: Dupilumab
Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
Treatment: Drugs: Placebo
Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
Treatment: Drugs: Inhaled corticosteroid (ICS) therapy
Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)
Treatment: Drugs: Albuterol/Salbutamol
Oral inhalation as needed
Treatment: Drugs: Levalbuterol/Levosalbutamol
Oral inhalation as needed
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population
Query!
Assessment method [1]
0
0
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Query!
Timepoint [1]
0
0
Baseline to Week 52
Query!
Primary outcome [2]
0
0
Absolute Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12: ITT Population
Query!
Assessment method [2]
0
0
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Query!
Timepoint [2]
0
0
Baseline, Week 12
Query!
Secondary outcome [1]
0
0
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population
Query!
Assessment method [1]
0
0
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Query!
Timepoint [1]
0
0
Baseline, Week 12
Query!
Secondary outcome [2]
0
0
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.15 Giga/L
Query!
Assessment method [2]
0
0
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Query!
Timepoint [2]
0
0
Baseline to Week 52
Query!
Secondary outcome [3]
0
0
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L
Query!
Assessment method [3]
0
0
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Query!
Timepoint [3]
0
0
Baseline, Week 12
Query!
Secondary outcome [4]
0
0
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.3 Giga/L
Query!
Assessment method [4]
0
0
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Query!
Timepoint [4]
0
0
Baseline to Week 52
Query!
Secondary outcome [5]
0
0
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L
Query!
Assessment method [5]
0
0
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Query!
Timepoint [5]
0
0
Baseline, Week 12
Query!
Secondary outcome [6]
0
0
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil <0.3 Giga/L
Query!
Assessment method [6]
0
0
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Query!
Timepoint [6]
0
0
Baseline to Week 52
Query!
Secondary outcome [7]
0
0
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With High Dose ICS at Baseline
Query!
Assessment method [7]
0
0
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Query!
Timepoint [7]
0
0
Baseline to Week 52
Query!
Secondary outcome [8]
0
0
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline
Query!
Assessment method [8]
0
0
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Query!
Timepoint [8]
0
0
Baseline, Week 12
Query!
Secondary outcome [9]
0
0
Change From Baseline in Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ [S]) Self-Administered Global Score at Week 24: ITT Population
Query!
Assessment method [9]
0
0
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Query!
Timepoint [9]
0
0
Baseline, Week 24
Query!
Secondary outcome [10]
0
0
Change From Baseline in AQLQ (S) Self- Administered Global Score at Week 24: ITT Population With Baseline Eosinophil >=0.3 Giga/L
Query!
Assessment method [10]
0
0
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Query!
Timepoint [10]
0
0
Baseline, Week 24
Query!
Secondary outcome [11]
0
0
Change From Baseline in Asthma Control Questionnaire 5-item Version (ACQ-5) Score at Week 24: ITT Population
Query!
Assessment method [11]
0
0
The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Query!
Timepoint [11]
0
0
Baseline, Week 24
Query!
Secondary outcome [12]
0
0
Annualized Rate of Severe Exacerbation Events Resulting in Hospitalization or Emergency Room Visit During The 52-Week Treatment Period: ITT Population
Query!
Assessment method [12]
0
0
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations (resulted hospitalization or emergency room visit) that occurred during the treatment period divided by the total number of participant-years treated.
Query!
Timepoint [12]
0
0
Baseline to Week 52
Query!
Secondary outcome [13]
0
0
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil <0.3 Giga/L
Query!
Assessment method [13]
0
0
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Query!
Timepoint [13]
0
0
Baseline, Week 12
Query!
Secondary outcome [14]
0
0
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L
Query!
Assessment method [14]
0
0
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Query!
Timepoint [14]
0
0
Baseline, Week 12
Query!
Secondary outcome [15]
0
0
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline
Query!
Assessment method [15]
0
0
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Query!
Timepoint [15]
0
0
Baseline, Week 12
Query!
Secondary outcome [16]
0
0
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L
Query!
Assessment method [16]
0
0
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Query!
Timepoint [16]
0
0
Baseline, Week 12
Query!
Secondary outcome [17]
0
0
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population
Query!
Assessment method [17]
0
0
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Query!
Timepoint [17]
0
0
Baseline, Weeks 2, 4, 8, 24, 36, and 52
Query!
Secondary outcome [18]
0
0
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population
Query!
Assessment method [18]
0
0
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Query!
Timepoint [18]
0
0
Baseline, Weeks 2, 4, 8, 24, 36, and 52
Query!
Secondary outcome [19]
0
0
Change From Baseline in Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
Query!
Assessment method [19]
0
0
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Query!
Timepoint [19]
0
0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Query!
Secondary outcome [20]
0
0
Change From Baseline in Morning (AM)/Evening (PM) Peak Expiratory Flow (PEF) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
Query!
Assessment method [20]
0
0
The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma.
Query!
Timepoint [20]
0
0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Query!
Secondary outcome [21]
0
0
Change From Baseline in Forced Vital Capacity (FVC) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
Query!
Assessment method [21]
0
0
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters.
Query!
Timepoint [21]
0
0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Query!
Secondary outcome [22]
0
0
Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
Query!
Assessment method [22]
0
0
FEF is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF25-75% is defined as the mean forced expiratory flow between the 25% and 75% of the FVC.
Query!
Timepoint [22]
0
0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Query!
Secondary outcome [23]
0
0
Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
Query!
Assessment method [23]
0
0
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Query!
Timepoint [23]
0
0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Query!
Secondary outcome [24]
0
0
Annualized Rate of Loss of Asthma Control (LOAC) Event During The 52-Week Treatment Period: ITT Population
Query!
Assessment method [24]
0
0
LOAC was defined as any of the following: >=6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS >=4 times the dose at randomization; use of systemic corticosteroids for >=3 days; hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of LOAC that occurred during the treatment period divided by the total number of participant-years treated.
Query!
Timepoint [24]
0
0
Baseline to Week 52
Query!
Secondary outcome [25]
0
0
Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population
Query!
Assessment method [25]
0
0
The time to first severe exacerbation was defined as follows: date of the first event - randomization date +1. For participants who had no event on or before Visit 18 (Week 52) or last contact date, the time was censored at the date of Visit 18 or the last contact date, whichever was earlier. The median time to first severe exacerbation was not estimated; therefore, the probability of severe exacerbation at Weeks 12, 24, 36, and 52, are presented as the descriptive statistics.
Query!
Timepoint [25]
0
0
Baseline up to Week 52
Query!
Secondary outcome [26]
0
0
Time to First LOAC Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population
Query!
Assessment method [26]
0
0
The time to first LOAC event was defined as follows: date of the first event - first dose date +1. For participants who had no event on or before last dose date + 14 days or last contact date, the time was censored at the last dose date + 14 days or the last contact date, whichever was earlier.
Query!
Timepoint [26]
0
0
Baseline up to Week 52
Query!
Secondary outcome [27]
0
0
Change From Baseline in ACQ-5 Score at Weeks 2, 4, 8, 12, 36, and 52: ITT Population
Query!
Assessment method [27]
0
0
The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Query!
Timepoint [27]
0
0
Baseline, Weeks 2, 4, 8, 12, 36, and 52
Query!
Secondary outcome [28]
0
0
Change From Baseline in Asthma Control Questionnaire 7-item Version (ACQ-7) Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
Query!
Assessment method [28]
0
0
The ACQ-7 has 7 questions, the first 5 questions assess the most common asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze plus short-acting bronchodilator use, and FEV1 (pre-bronchodilator % predicted). Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). Clinic staff scored the FEV1% predicted on a 7-point scale. The questions were equally weighted and the ACQ-7 total score was mean of the scores of all 7 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Query!
Timepoint [28]
0
0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Query!
Secondary outcome [29]
0
0
Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
Query!
Assessment method [29]
0
0
Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as: 0= No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning, no night time awakenings, 2= Woke up once because of asthma (including early awakening), 3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.
Query!
Timepoint [29]
0
0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Query!
Secondary outcome [30]
0
0
Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
Query!
Assessment method [30]
0
0
Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.
Query!
Timepoint [30]
0
0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Query!
Secondary outcome [31]
0
0
Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
Query!
Assessment method [31]
0
0
Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night.
Query!
Timepoint [31]
0
0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Query!
Secondary outcome [32]
0
0
Change From Baseline in Number of Puffs of Daily Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
Query!
Assessment method [32]
0
0
Participants might administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed during the study. The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations were recorded daily by the participants in an electronic diary/peak expiratory flow (PEF) meter. In the case that Nebulizer solutions were used as an alternative delivery method, the nebulizer dose was converted to number of puffs as per following conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) corresponds to 4 puffs.
Query!
Timepoint [32]
0
0
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Query!
Secondary outcome [33]
0
0
Change From Baseline in AQLQ (S) Self-Administered Global Score at Weeks 12, 36, and 52: ITT Population
Query!
Assessment method [33]
0
0
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Query!
Timepoint [33]
0
0
Baseline, Weeks 12, 36, and 52
Query!
Secondary outcome [34]
0
0
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Weeks 12, 24, 36, and 52: ITT Population
Query!
Assessment method [34]
0
0
EQ-5D-5L is a standardized health-related quality of life questionnaire developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-5L-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).
Query!
Timepoint [34]
0
0
Baseline, Weeks 12, 24, 36, and 52
Query!
Secondary outcome [35]
0
0
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12, 24, 36, and 52: ITT Population
Query!
Assessment method [35]
0
0
The HADS is a general scale to detect states of anxiety and depression already used and validated in asthma, which includes HADS-A and HADS-D subscales. The instrument is comprised of 14 items: 7 related to anxiety (HADS-A) and 7 to depression (HADS-D). Each item on the questionnaire is scored from 0-3. The anxiety/depression score is the sum of the scores of the 7 related items; one can score between 0 and 21 for either anxiety or depression. And the total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher anxiety/depression complains.
Query!
Timepoint [35]
0
0
Baseline, Weeks 12, 24, 36, and 52
Query!
Secondary outcome [36]
0
0
Change From Baseline in 22-Item Sino Nasal Outcome Test (SNOT-22) Score at Weeks 12, 24, 36, and 52: ITT Population With Bilateral Nasal Polyposis/Chronic Rhinosinusitis
Query!
Assessment method [36]
0
0
The SNOT-22 is a validated measure of health related quality of life in sinonasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.
Query!
Timepoint [36]
0
0
Baseline, Weeks 12, 24, 36, and 52
Query!
Secondary outcome [37]
0
0
Change From Baseline in Standardized Rhinoconjunctivitis Quality Of Life Questionnaire, Ages 12+ (RQLQ[S]+12) Score at Weeks 12, 24, 36, and 52: ITT Population With Comorbid Allergic Rhinitis
Query!
Assessment method [37]
0
0
RQLQ(S)+12 is a self-administered questionnaire with standardized activities developed to measure health-related quality of life signs and symptoms that are most problematic in those 12 to 75 years of age, as a result of perennial or seasonal allergic rhinitis. There are 28 items on RQLQ(S) in 7 domains: activities (3 items), sleep (3 items), non-nose/eye symptoms (7 items), practical problems (3 items), nasal symptoms (4 items), eye symptoms (4 items) and emotional (4 items). RQLQ(S)+12 responses are based on 7-point likert scale with responses ranging from 0 (not troubled) to 6 (extremely troubled). Individual items within RQLQ(S)+12 are equally weighted. The overall score is calculated as the mean score of all items. Higher scores indicated more health-related quality of life impairment (lower scores better).
Query!
Timepoint [37]
0
0
Baseline, Weeks 12, 24, 36, and 52
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
-Adults and adolescent participants with a physician diagnosis of asthma for =12 months,
based on the Global Initiative for Asthma (GINA) 2014 Guidelines and the following
criteria:
a) Existing treatment with medium to high dose ICS (=250 mcg of fluticasone propionate
twice daily or equipotent ICS daily dosage to a maximum of 2000 mcg/day of fluticasone
propionate or equivalent) in combination with a second controller (eg, long-acting beta
agonist, leukotriene receptor antagonist) for at least 3 months with a stable dose =1 month
prior to Visit 1.
i) Note for Japan: for participants aged 18 years and older, ICS must be on =200 mcg of
fluticasone propionate twice daily or equivalent; for participants aged 12 to 17 years, ICS
must be =100 mcg of fluticasone propionate twice daily or equivalent).
ii) Participants requiring a third controller for their asthma will be considered eligible
for this study, and it should also be used for at least 3 months with a stable dose =1
month prior to Visit 1.
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- Participants <12 years of age or the minimum legal age for adolescents in the country
of the investigative site, whichever is higher (For those countries where local
regulations permit enrollment of adults only, participant recruitment will be
restricted to those who are =18 years of age).
- Weight is less than 30 kilograms.
- Chronic obstructive pulmonary disease or other lung diseases (eg, idiopathic pulmonary
fibrosis, Churg-Strauss Syndrome, etc) which may impair lung function.
- A participant who experiences a severe asthma exacerbation (defined as a deterioration
of asthma that results in emergency treatment, hospitalization due to asthma, or
treatment with systemic steroids at any time from 1 month prior to the Screening Visit
up to and including the Baseline Visit).
- Evidence of lung disease(s) other than asthma, either clinical evidence or imaging
(Chest X-ray, CT, MRI) within 12 months of Visit 1 or at the screening visit, as per
local standard of care.
- Note for Japan: According to the request from the health authority, chest X-ray should
be performed at screening visit if there is no chest imaging (Chest X-ray, computed
tomography [CT], magnetic resonance imaging [MRI]) available within 3 months prior to
screening to exclude participants with suspected active or untreated latent
tuberculosis.
- Current smoker or cessation of smoking within 6 months prior to Visit 1.
- Previous smoker with a smoking history >10 pack-years.
- Comorbid disease that might interfere with the evaluation of Investigational Medicinal
Product.
The above information is not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/04/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
23/11/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1902
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Investigational Site Number 036005 - Campbelltown
Query!
Recruitment hospital [2]
0
0
Investigational Site Number 036001 - Clayton
Query!
Recruitment hospital [3]
0
0
Investigational Site Number 036002 - Frankston
Query!
Recruitment hospital [4]
0
0
Investigational Site Number 036006 - Glen Osmond
Query!
Recruitment hospital [5]
0
0
Investigational Site Number 036003 - Murdoch
Query!
Recruitment hospital [6]
0
0
Investigational Site Number 036004 - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2560 - Campbelltown
Query!
Recruitment postcode(s) [2]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [3]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [4]
0
0
5064 - Glen Osmond
Query!
Recruitment postcode(s) [5]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [6]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Idaho
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Illinois
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Iowa
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kentucky
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maine
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Maryland
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Massachusetts
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Minnesota
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Missouri
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Montana
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Nebraska
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New Jersey
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
New York
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
North Carolina
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Ohio
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Oklahoma
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Oregon
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Pennsylvania
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Rhode Island
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
South Carolina
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Texas
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Utah
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Vermont
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Virginia
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Washington
Query!
Country [34]
0
0
Argentina
Query!
State/province [34]
0
0
Bahia Blanca
Query!
Country [35]
0
0
Argentina
Query!
State/province [35]
0
0
Buenos Aires
Query!
Country [36]
0
0
Argentina
Query!
State/province [36]
0
0
Caba
Query!
Country [37]
0
0
Argentina
Query!
State/province [37]
0
0
Capital Federal
Query!
Country [38]
0
0
Argentina
Query!
State/province [38]
0
0
La Plata
Query!
Country [39]
0
0
Argentina
Query!
State/province [39]
0
0
Rosario
Query!
Country [40]
0
0
Argentina
Query!
State/province [40]
0
0
San Miguel De Tucuman
Query!
Country [41]
0
0
Argentina
Query!
State/province [41]
0
0
San Miguel De Tucumán
Query!
Country [42]
0
0
Brazil
Query!
State/province [42]
0
0
Florianópolis
Query!
Country [43]
0
0
Brazil
Query!
State/province [43]
0
0
Porto Alegre
Query!
Country [44]
0
0
Brazil
Query!
State/province [44]
0
0
Salvador
Query!
Country [45]
0
0
Brazil
Query!
State/province [45]
0
0
Sao Paulo
Query!
Country [46]
0
0
Brazil
Query!
State/province [46]
0
0
Sorocaba
Query!
Country [47]
0
0
Brazil
Query!
State/province [47]
0
0
São Bernardo Do Campo
Query!
Country [48]
0
0
Canada
Query!
State/province [48]
0
0
Burlington
Query!
Country [49]
0
0
Canada
Query!
State/province [49]
0
0
Calgary
Query!
Country [50]
0
0
Canada
Query!
State/province [50]
0
0
Mississauga
Query!
Country [51]
0
0
Canada
Query!
State/province [51]
0
0
Montreal
Query!
Country [52]
0
0
Canada
Query!
State/province [52]
0
0
Ottawa
Query!
Country [53]
0
0
Canada
Query!
State/province [53]
0
0
Quebec
Query!
Country [54]
0
0
Canada
Query!
State/province [54]
0
0
Sherbrooke
Query!
Country [55]
0
0
Canada
Query!
State/province [55]
0
0
Toronto
Query!
Country [56]
0
0
Canada
Query!
State/province [56]
0
0
Trois-Rivieres
Query!
Country [57]
0
0
Canada
Query!
State/province [57]
0
0
Vancouver
Query!
Country [58]
0
0
Chile
Query!
State/province [58]
0
0
Concepción
Query!
Country [59]
0
0
Chile
Query!
State/province [59]
0
0
Quillota
Query!
Country [60]
0
0
Chile
Query!
State/province [60]
0
0
Santiago
Query!
Country [61]
0
0
Chile
Query!
State/province [61]
0
0
Talcahuano
Query!
Country [62]
0
0
Chile
Query!
State/province [62]
0
0
Talca
Query!
Country [63]
0
0
Chile
Query!
State/province [63]
0
0
Temuco
Query!
Country [64]
0
0
Chile
Query!
State/province [64]
0
0
Valdivia
Query!
Country [65]
0
0
Chile
Query!
State/province [65]
0
0
Viña Del Mar
Query!
Country [66]
0
0
Colombia
Query!
State/province [66]
0
0
Bogota
Query!
Country [67]
0
0
Colombia
Query!
State/province [67]
0
0
Bogotá
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Brest
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Lille Cedex
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Lille
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Lyon
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Marseille
Query!
Country [73]
0
0
France
Query!
State/province [73]
0
0
Montpellier
Query!
Country [74]
0
0
France
Query!
State/province [74]
0
0
Nantes Cedex 1
Query!
Country [75]
0
0
France
Query!
State/province [75]
0
0
Paris
Query!
Country [76]
0
0
France
Query!
State/province [76]
0
0
Strasbourg
Query!
Country [77]
0
0
France
Query!
State/province [77]
0
0
Vandoeuvre-Les-Nancy
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Berlin
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Bochum
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Frankfurt Am Main
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Hannover
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Koblenz
Query!
Country [83]
0
0
Germany
Query!
State/province [83]
0
0
Lübeck
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Mainz
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Rüdersdorf
Query!
Country [86]
0
0
Hungary
Query!
State/province [86]
0
0
Gödöllö
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
Ancona
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Catania
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Ferrara
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
Firenze
Query!
Country [91]
0
0
Italy
Query!
State/province [91]
0
0
Foggia
Query!
Country [92]
0
0
Italy
Query!
State/province [92]
0
0
Modena
Query!
Country [93]
0
0
Italy
Query!
State/province [93]
0
0
Palermo
Query!
Country [94]
0
0
Italy
Query!
State/province [94]
0
0
Pisa
Query!
Country [95]
0
0
Italy
Query!
State/province [95]
0
0
Reggio Emilia
Query!
Country [96]
0
0
Italy
Query!
State/province [96]
0
0
Torino
Query!
Country [97]
0
0
Japan
Query!
State/province [97]
0
0
Akashi-Shi
Query!
Country [98]
0
0
Japan
Query!
State/province [98]
0
0
Asahikawa-Shi
Query!
Country [99]
0
0
Japan
Query!
State/province [99]
0
0
Chiyoda-Ku
Query!
Country [100]
0
0
Japan
Query!
State/province [100]
0
0
Chuo-Ku
Query!
Country [101]
0
0
Japan
Query!
State/province [101]
0
0
Fukui-Shi
Query!
Country [102]
0
0
Japan
Query!
State/province [102]
0
0
Fukuoka-Shi
Query!
Country [103]
0
0
Japan
Query!
State/province [103]
0
0
Fukuyama-Shi
Query!
Country [104]
0
0
Japan
Query!
State/province [104]
0
0
Habikino-Shi
Query!
Country [105]
0
0
Japan
Query!
State/province [105]
0
0
Higashiosaka-Shi
Query!
Country [106]
0
0
Japan
Query!
State/province [106]
0
0
Himeji-Shi
Query!
Country [107]
0
0
Japan
Query!
State/province [107]
0
0
Hiroshima-Shi
Query!
Country [108]
0
0
Japan
Query!
State/province [108]
0
0
Iizuka-Shi
Query!
Country [109]
0
0
Japan
Query!
State/province [109]
0
0
Isesaki-Shi
Query!
Country [110]
0
0
Japan
Query!
State/province [110]
0
0
Itabashi-Ku
Query!
Country [111]
0
0
Japan
Query!
State/province [111]
0
0
Kagoshima-Shi
Query!
Country [112]
0
0
Japan
Query!
State/province [112]
0
0
Kanazawa-Shi
Query!
Country [113]
0
0
Japan
Query!
State/province [113]
0
0
Kasuga-Shi
Query!
Country [114]
0
0
Japan
Query!
State/province [114]
0
0
Kawaguchi-Shi
Query!
Country [115]
0
0
Japan
Query!
State/province [115]
0
0
Kishiwada-Shi
Query!
Country [116]
0
0
Japan
Query!
State/province [116]
0
0
Kobe-Shi
Query!
Country [117]
0
0
Japan
Query!
State/province [117]
0
0
Kodaira-Shi
Query!
Country [118]
0
0
Japan
Query!
State/province [118]
0
0
Kokubunji-Shi
Query!
Country [119]
0
0
Japan
Query!
State/province [119]
0
0
Koshi-Shi
Query!
Country [120]
0
0
Japan
Query!
State/province [120]
0
0
Koshigaya-Shi
Query!
Country [121]
0
0
Japan
Query!
State/province [121]
0
0
Kurashiki-Shi
Query!
Country [122]
0
0
Japan
Query!
State/province [122]
0
0
Kyoto-Shi
Query!
Country [123]
0
0
Japan
Query!
State/province [123]
0
0
Machida-Shi
Query!
Country [124]
0
0
Japan
Query!
State/province [124]
0
0
Matsuyama-Shi
Query!
Country [125]
0
0
Japan
Query!
State/province [125]
0
0
Mibu
Query!
Country [126]
0
0
Japan
Query!
State/province [126]
0
0
Minato-Ku
Query!
Country [127]
0
0
Japan
Query!
State/province [127]
0
0
Mizunami-Shi
Query!
Country [128]
0
0
Japan
Query!
State/province [128]
0
0
Muroran-Shi
Query!
Country [129]
0
0
Japan
Query!
State/province [129]
0
0
Nagakute-Shi
Query!
Country [130]
0
0
Japan
Query!
State/province [130]
0
0
Nagoya-Shi
Query!
Country [131]
0
0
Japan
Query!
State/province [131]
0
0
Naka-Gun
Query!
Country [132]
0
0
Japan
Query!
State/province [132]
0
0
Nakano-Ku
Query!
Country [133]
0
0
Japan
Query!
State/province [133]
0
0
Naruto-Shi
Query!
Country [134]
0
0
Japan
Query!
State/province [134]
0
0
Obihiro-Shi
Query!
Country [135]
0
0
Japan
Query!
State/province [135]
0
0
Ome-Shi
Query!
Country [136]
0
0
Japan
Query!
State/province [136]
0
0
Osaka Sayama-Shi
Query!
Country [137]
0
0
Japan
Query!
State/province [137]
0
0
Osaki-Shi
Query!
Country [138]
0
0
Japan
Query!
State/province [138]
0
0
Ota-Ku
Query!
Country [139]
0
0
Japan
Query!
State/province [139]
0
0
Ota-Shi
Query!
Country [140]
0
0
Japan
Query!
State/province [140]
0
0
Oura-Gun
Query!
Country [141]
0
0
Japan
Query!
State/province [141]
0
0
Sagamihara-Shi
Query!
Country [142]
0
0
Japan
Query!
State/province [142]
0
0
Sapporo-Shi
Query!
Country [143]
0
0
Japan
Query!
State/province [143]
0
0
Seto-Shi
Query!
Country [144]
0
0
Japan
Query!
State/province [144]
0
0
Shibuya-Ku
Query!
Country [145]
0
0
Japan
Query!
State/province [145]
0
0
Shinagawa-Ku
Query!
Country [146]
0
0
Japan
Query!
State/province [146]
0
0
Shinjuku-Ku
Query!
Country [147]
0
0
Japan
Query!
State/province [147]
0
0
Sumida-Ku
Query!
Country [148]
0
0
Japan
Query!
State/province [148]
0
0
Tachikawa-Shi
Query!
Country [149]
0
0
Japan
Query!
State/province [149]
0
0
Tokyo
Query!
Country [150]
0
0
Japan
Query!
State/province [150]
0
0
Tomakomai-Shi
Query!
Country [151]
0
0
Japan
Query!
State/province [151]
0
0
Tsu-Shi
Query!
Country [152]
0
0
Japan
Query!
State/province [152]
0
0
Uozu-Shi
Query!
Country [153]
0
0
Japan
Query!
State/province [153]
0
0
Urasoe-Shi
Query!
Country [154]
0
0
Japan
Query!
State/province [154]
0
0
Uruma-Shi
Query!
Country [155]
0
0
Japan
Query!
State/province [155]
0
0
Wakayama-Shi
Query!
Country [156]
0
0
Japan
Query!
State/province [156]
0
0
Yokohama-Shi
Query!
Country [157]
0
0
Japan
Query!
State/province [157]
0
0
Yonago-Shi
Query!
Country [158]
0
0
Korea, Republic of
Query!
State/province [158]
0
0
Bucheon-Si
Query!
Country [159]
0
0
Korea, Republic of
Query!
State/province [159]
0
0
Busan
Query!
Country [160]
0
0
Korea, Republic of
Query!
State/province [160]
0
0
Cheongju-Si
Query!
Country [161]
0
0
Korea, Republic of
Query!
State/province [161]
0
0
Incheon
Query!
Country [162]
0
0
Korea, Republic of
Query!
State/province [162]
0
0
Seoul
Query!
Country [163]
0
0
Korea, Republic of
Query!
State/province [163]
0
0
Suwon
Query!
Country [164]
0
0
Korea, Republic of
Query!
State/province [164]
0
0
Uijeongbu-Si
Query!
Country [165]
0
0
Mexico
Query!
State/province [165]
0
0
Chihuahua
Query!
Country [166]
0
0
Mexico
Query!
State/province [166]
0
0
Cuautitlan Izcalli
Query!
Country [167]
0
0
Mexico
Query!
State/province [167]
0
0
Durango
Query!
Country [168]
0
0
Mexico
Query!
State/province [168]
0
0
Guadalajara
Query!
Country [169]
0
0
Mexico
Query!
State/province [169]
0
0
Mexico City
Query!
Country [170]
0
0
Mexico
Query!
State/province [170]
0
0
Monterrey
Query!
Country [171]
0
0
Mexico
Query!
State/province [171]
0
0
México
Query!
Country [172]
0
0
Mexico
Query!
State/province [172]
0
0
San Juan Del Rio
Query!
Country [173]
0
0
Mexico
Query!
State/province [173]
0
0
Veracruz
Query!
Country [174]
0
0
Mexico
Query!
State/province [174]
0
0
Zapopan
Query!
Country [175]
0
0
Poland
Query!
State/province [175]
0
0
Bialystok
Query!
Country [176]
0
0
Poland
Query!
State/province [176]
0
0
Gdansk
Query!
Country [177]
0
0
Poland
Query!
State/province [177]
0
0
Krakow
Query!
Country [178]
0
0
Poland
Query!
State/province [178]
0
0
Lodz
Query!
Country [179]
0
0
Poland
Query!
State/province [179]
0
0
Poznan
Query!
Country [180]
0
0
Poland
Query!
State/province [180]
0
0
Sopot
Query!
Country [181]
0
0
Poland
Query!
State/province [181]
0
0
Strzelce Opolskie
Query!
Country [182]
0
0
Russian Federation
Query!
State/province [182]
0
0
Ekaterinburg
Query!
Country [183]
0
0
Russian Federation
Query!
State/province [183]
0
0
Moscow
Query!
Country [184]
0
0
Russian Federation
Query!
State/province [184]
0
0
Ryazan
Query!
Country [185]
0
0
Russian Federation
Query!
State/province [185]
0
0
Saint-Petersburg
Query!
Country [186]
0
0
Russian Federation
Query!
State/province [186]
0
0
St-Petersburg
Query!
Country [187]
0
0
Russian Federation
Query!
State/province [187]
0
0
Yaroslavl
Query!
Country [188]
0
0
South Africa
Query!
State/province [188]
0
0
Brandfort
Query!
Country [189]
0
0
South Africa
Query!
State/province [189]
0
0
Cape Town
Query!
Country [190]
0
0
South Africa
Query!
State/province [190]
0
0
Durban
Query!
Country [191]
0
0
South Africa
Query!
State/province [191]
0
0
Pretoria
Query!
Country [192]
0
0
Spain
Query!
State/province [192]
0
0
Barcelona
Query!
Country [193]
0
0
Spain
Query!
State/province [193]
0
0
Palma De Mallorca
Query!
Country [194]
0
0
Spain
Query!
State/province [194]
0
0
Pozuelo De Alarcón
Query!
Country [195]
0
0
Spain
Query!
State/province [195]
0
0
Sant Boi De Llobregat
Query!
Country [196]
0
0
Spain
Query!
State/province [196]
0
0
Santiago De Compostela
Query!
Country [197]
0
0
Spain
Query!
State/province [197]
0
0
Sevilla
Query!
Country [198]
0
0
Spain
Query!
State/province [198]
0
0
Valencia
Query!
Country [199]
0
0
Taiwan
Query!
State/province [199]
0
0
Kaohsiung
Query!
Country [200]
0
0
Taiwan
Query!
State/province [200]
0
0
New Taipei City
Query!
Country [201]
0
0
Taiwan
Query!
State/province [201]
0
0
Taichung
Query!
Country [202]
0
0
Taiwan
Query!
State/province [202]
0
0
Taipei
Query!
Country [203]
0
0
Taiwan
Query!
State/province [203]
0
0
Taoyuan
Query!
Country [204]
0
0
Turkey
Query!
State/province [204]
0
0
Ankara
Query!
Country [205]
0
0
Turkey
Query!
State/province [205]
0
0
Bursa
Query!
Country [206]
0
0
Turkey
Query!
State/province [206]
0
0
Istanbul
Query!
Country [207]
0
0
Turkey
Query!
State/province [207]
0
0
Izmir
Query!
Country [208]
0
0
Turkey
Query!
State/province [208]
0
0
Kirikkale
Query!
Country [209]
0
0
Turkey
Query!
State/province [209]
0
0
Kocaeli
Query!
Country [210]
0
0
Turkey
Query!
State/province [210]
0
0
Mersin
Query!
Country [211]
0
0
Turkey
Query!
State/province [211]
0
0
Rize
Query!
Country [212]
0
0
Ukraine
Query!
State/province [212]
0
0
Chernivtsi
Query!
Country [213]
0
0
Ukraine
Query!
State/province [213]
0
0
Dnipro
Query!
Country [214]
0
0
Ukraine
Query!
State/province [214]
0
0
Ivano-Frankivsk
Query!
Country [215]
0
0
Ukraine
Query!
State/province [215]
0
0
Kharkiv
Query!
Country [216]
0
0
Ukraine
Query!
State/province [216]
0
0
Kyiv
Query!
Country [217]
0
0
Ukraine
Query!
State/province [217]
0
0
Odessa
Query!
Country [218]
0
0
Ukraine
Query!
State/province [218]
0
0
Poltava
Query!
Country [219]
0
0
Ukraine
Query!
State/province [219]
0
0
Ternopil
Query!
Country [220]
0
0
Ukraine
Query!
State/province [220]
0
0
Vinnytsya
Query!
Country [221]
0
0
Ukraine
Query!
State/province [221]
0
0
Zaporizhia
Query!
Country [222]
0
0
United Kingdom
Query!
State/province [222]
0
0
Bradford
Query!
Country [223]
0
0
United Kingdom
Query!
State/province [223]
0
0
London
Query!
Country [224]
0
0
United Kingdom
Query!
State/province [224]
0
0
Newcastle Upon Tyne
Query!
Country [225]
0
0
United Kingdom
Query!
State/province [225]
0
0
Portsmouth
Query!
Country [226]
0
0
United Kingdom
Query!
State/province [226]
0
0
South Shields
Query!
Country [227]
0
0
United Kingdom
Query!
State/province [227]
0
0
Sutton-In-Ashfield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Regeneron Pharmaceuticals
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Primary Objective:
To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent
asthma.
Secondary Objectives:
- To evaluate the safety and tolerability of dupilumab.
- To evaluate the effect of dupilumab on improving participant-reported outcomes including
health-related quality of life.
- To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02414854
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Sciences & Operations
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02414854
Download to PDF